Over the last years, the prevalence of Candida albicans infections in humans has increased seriously (40). The two main reasons are the increasing number of immunocompromised patients and the increasing resistance against the limited number of antimycotic drugs that are commercially available. These drugs act on a small number of targets. They either bind ergosterol or inhibit its biosynthesis (amphotericin B, terbinafine, nystatin, and the azoles) or interfere with nucleic acid biosynthesis (flucytosine). New drugs still under clinical investigation act on cell wall formation or on protein synthesis (echinocandins, nikkomycins and aureobasidin, rustmicin, and khafrefungin) (23, 35). A major problem for development of new antifungal compounds is the fact that fungi are eukaryotes and therefore have most essential functions in common with mammalian cells. Recently, much research focus has gone to targets involved in the regulation of the dimorphic shift from yeast cells to hyphae, since it has been shown that the capacity to form hyphae is related to virulence (12, 20, 30). Based on the similarity with pathways involved in the control of pseudohyphal growth in Saccharomyces cerevisiae (38), the mitogen-activated protein (MAP) kinase pathway and the Ras-cyclic AMP pathway have been identified as being involved in control of C. albicans dimorphism. The MAP kinase pathway includes Cst20, Hst7, Cek1, and Cph1 (14, 16, 27, 33), while the Ras-cyclic AMP pathway includes Ras1, Cap1, Tpk2, and Efg1 (3, 17, 43, 45). Although deletion of these genes renders C. albicans cells less virulent or even avirulent in a mouse model, the gene products do not seem to be promising as antifungal targets because homologous components are present in mammals. A similar situation applies to the Hog1 MAP kinase pathway (1, 33, 34). More promising are signaling pathways involved in cell wall formation, and for some of the components clinical studies to investigate their potential as antifungal targets are under way (8, 10, 32, 42, 44, 49). Another class of interesting targets are important for adherence to host cells. Two groups, the secreted acid protease family genes and the cell surface glycoprotein family genes, have been identified, and their deletion results in lower virulence (9, 20, 25, 41). Trehalose metabolism might be an interesting target for antifungals. It is entirely absent in mammalian cells and makes use of highly specific enzymes. Trehalose (α,α,1,1-diglucose) is synthesized in fungi in a two-step process. Trehalose-6-phosphate (Tre6P) synthase, encoded by TPS1, synthesizes Tre6P from glucose-6-phosphate and UDPglucose (4). Tre6P is then hydrolyzed into trehalose by Tre6P phosphatase, encoded by TPS2 (15). Trehalose is a storage carbohydrate, but it also plays a major role as stress protectant (47, 51, 53). It appears that trehalose has unusual chemical properties which make it more suitable than other sugars to protect proteins and membranes against denaturation under stress conditions (13, 37). It accumulates in large quantities in survival forms of a diverse array of organisms and also accumulates in vegetative cells of fungi under stress conditions (47, 51, 53). Since pathogens are living under adverse conditions in host organisms because of the host defense reactions, insufficient nutrient supply, or high osmolarity, etc., one can assume that their stress response mechanisms are continuously activated. Trehalose accumulation is part of the stress response, and previous work has shown that prevention of trehalose accumulation by deletion of the C. albicans TPS1 gene renders the cells less virulent (54). In S. cerevisiae, deletion of the TPS2 gene encoding Tre6P phosphatase causes hyperaccumulation of Tre6P instead of trehalose under stress conditions (15, 39). As a result, a tps2Δ strain is thermosensitive. Tre6P accumulation is toxic because it sequestrates phosphate and as a result inhibits ATP generation. Moreover, Tre6P is an inhibitor of hexokinase, causing additional reduction of glycolytic flux and energy generation (6, 48). Energy provision is required for most cellular functions, including the activity of drug efflux pumps. Because of these reasons, it appeared to us that Tre6P phosphatase might be even a better target for antifungals than Tre6P synthase. Moreover, not only is Tre6P phosphatase absent in mammals, its substrate Tre6P is also absent, increasing the chances for design of specific inhibitors. Disruption of the C. albicans TPS1 gene (CaTPS1) impairs the formation of hyphae on glucose-containing medium and decreases virulence in a mouse systemic infection model (2, 54). The reason for the lower virulence is not well understood. There are at least two possibilities. First, deletion of TPS1 in other yeasts such as S. cerevisiae or Kluyveromyces lactis results in complete deregulation of glycolysis after addition of glucose and rapid loss of viability (31, 50). In C. albicans, a similar deregulation of metabolism is found but only at higher temperatures. Second, the absence of trehalose may result in lower stress resistance and as a result lower virulence. If the absence of trehalose is the main reason for the reduced virulence, it appears that deletion of the C. albicans TPS2 gene (CaTPS2), which results in high levels of Tre6P instead of trehalose, should at least give the same reduction in stress resistance and virulence. Because of the toxic effects of Tre6P hyperaccumulation on glycolysis, inactivation of CaTPS2 might impair cellular functions even more and therefore further reduce virulence. In this work we have cloned the CaTPS2 gene and constructed hetero- and homozygous deletion mutants. We show that complete inactivation of CaTPS2 results in a 50-fold increase in Tre6P levels, growth inhibition, and loss of viability during heat stress. Whereas deletion of CaTPS1 prevented glucose-induced hypha formation (54), deletion of CaTPS2 did not affect hypha formation under all conditions examined. In spite of this, virulence of the homozygous deletion mutant in a mouse systemic infection model was strongly reduced.